MX2010001631A - Amidas biciclicas para mejorar las respuestas sinapticas glutamatergicas. - Google Patents

Amidas biciclicas para mejorar las respuestas sinapticas glutamatergicas.

Info

Publication number
MX2010001631A
MX2010001631A MX2010001631A MX2010001631A MX2010001631A MX 2010001631 A MX2010001631 A MX 2010001631A MX 2010001631 A MX2010001631 A MX 2010001631A MX 2010001631 A MX2010001631 A MX 2010001631A MX 2010001631 A MX2010001631 A MX 2010001631A
Authority
MX
Mexico
Prior art keywords
syndrome
disorders
treatment
sleep apnea
compounds
Prior art date
Application number
MX2010001631A
Other languages
English (en)
Inventor
Rudolf Mueller
Original Assignee
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharma Inc filed Critical Cortex Pharma Inc
Publication of MX2010001631A publication Critical patent/MX2010001631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Abstract

La presente invención se relaciona con compuestos, composiciones farmacéuticas y métodos para uso en la prevención y tratamiento de insuficiencia cerebral, incluyendo mejoramiento del receptor que funciona en la sinapsis en redes cerebrales responsables de comportamientos básicos y de orden mayor. Estas redes cerebrales, están involucradas en la regulación de la respiración, y las capacidades cognitivas relacionadas con el deterioro de la memoria, tal como se observa en una variedad de demencias, en desequilibrios en la actividad neuronal entre diferentes regiones del cerebro, cómo se manifiesta en trastornos tales como enfermedad de Parkinson, esquizofrenia, depresión respiratoria, apneas del sueño, trastorno de hiperactividad de déficit de la atención y trastornos afectivos y del estado de ánimo, y en trastornos en donde está implicada una deficiencia en factores neurotróficos, así como en trastornos de la respiración tales como sobredosis de un alcohol, un opiato, un opioide, un barbiturato, un anestésico, o una toxina nerviosa, o en donde la depresión respiratoria resulta de una condición médica tal como apnea del sueño central, apnea del sueño central inducida por accidente cerebrovascular, apnea del sueño obstructiva, síndrome de hipoventilación congénita, síndrome de hipoventilación por obesidad, síndrome de muerte infantil repentina, síndrome de Rett, lesión de la médula espinal, lesión cerebral traumática, respiración de Cheney-Stokes, maldición de Ondina, síndrome de Prader-Willi y ahogamiento. En un aspecto particular, la invención se relaciona con compuestos de amida bicíclica útiles para el tratamiento de tales condiciones, y con métodos para el uso de estos compuestos para el tratamiento.
MX2010001631A 2007-08-10 2008-08-08 Amidas biciclicas para mejorar las respuestas sinapticas glutamatergicas. MX2010001631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96436207P 2007-08-10 2007-08-10
PCT/US2008/009508 WO2009023126A2 (en) 2007-08-10 2008-08-08 Bicyclic amides for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
MX2010001631A true MX2010001631A (es) 2010-03-15

Family

ID=40351347

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010001630A MX2010001630A (es) 2007-08-10 2008-08-08 Amidas bicíclicas para mejorar las respuestas sinápticas glutamatergícas.
MX2010001631A MX2010001631A (es) 2007-08-10 2008-08-08 Amidas biciclicas para mejorar las respuestas sinapticas glutamatergicas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010001630A MX2010001630A (es) 2007-08-10 2008-08-08 Amidas bicíclicas para mejorar las respuestas sinápticas glutamatergícas.

Country Status (16)

Country Link
US (3) US8263591B2 (es)
EP (1) EP2187888B1 (es)
JP (2) JP5576277B2 (es)
KR (2) KR20100045507A (es)
CN (2) CN101862330A (es)
AU (2) AU2008287445A1 (es)
BR (2) BRPI0814149A2 (es)
CA (2) CA2695742C (es)
ES (1) ES2560095T3 (es)
HK (1) HK1147677A1 (es)
MX (2) MX2010001630A (es)
NZ (1) NZ583823A (es)
RU (2) RU2010106975A (es)
SG (1) SG163526A1 (es)
WO (1) WO2009023126A2 (es)
ZA (1) ZA201001691B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139446B2 (ja) 2007-01-03 2013-02-06 レ ラボラトワール セルヴィエ グルタミン酸作動性シナプス応答を増強する３−置換−［１，２，３］−ベンゾトリアジノン化合物
ES2657054T3 (es) 2007-05-17 2018-03-01 Respirerx Pharmaceuticals Inc. Amidas disustituidas para mejorar las respuestas sinápticas glutamatérgicas
WO2009023126A2 (en) 2007-08-10 2009-02-19 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
SG173168A1 (en) * 2009-02-02 2011-08-29 Cortex Pharma Inc Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
EP2811997B1 (en) * 2012-02-07 2018-04-11 Eolas Therapeutics Inc. Substituted prolines/piperidines as orexin receptor antagonists
WO2016025669A1 (en) 2014-08-13 2016-02-18 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
US9739787B2 (en) 2015-09-01 2017-08-22 Abdulmohsen Ebrahim Alterki Method for diagnosing sleep apnea by measuring adipsin and betatrophin levels
LT3414241T (lt) 2016-02-12 2022-08-25 Astrazeneca Ab Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai
US20190112300A1 (en) * 2016-03-29 2019-04-18 Arnold Stan Lippa Compositions And Methods For Treating Attention Deficit Disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) * 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
FR2597103B1 (fr) * 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
ATE253909T1 (de) * 1992-07-24 2003-11-15 Univ California Arzneimittel die den durch ampa rezeptoren vermittelten synaptischen response erhöhen
US20020099050A1 (en) 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
AU4416197A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
PT1026950E (pt) 1997-10-27 2006-06-30 Cortex Pharma Inc Tratamento da esquizofrenia com ampaquinas e neurolepticos
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
TR200002427T2 (tr) 1998-02-18 2001-01-22 Neurosearch A/S Yeni bileşikler ve bunların pozitif ampa reseptör modülatörleri olarak kullanımı.
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
AUPS255202A0 (en) 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
WO2004089416A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
US20050085446A1 (en) 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN101600436A (zh) 2006-08-31 2009-12-09 艾伯塔大学校董 使用正变构ampa受体调节剂抑制呼吸抑制的方法
AP2009004915A0 (en) 2007-01-03 2009-08-31 Cortex Pharma Inc 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
JP5139446B2 (ja) 2007-01-03 2013-02-06 レ ラボラトワール セルヴィエ グルタミン酸作動性シナプス応答を増強する３−置換−［１，２，３］−ベンゾトリアジノン化合物
ES2657054T3 (es) * 2007-05-17 2018-03-01 Respirerx Pharmaceuticals Inc. Amidas disustituidas para mejorar las respuestas sinápticas glutamatérgicas
WO2009023126A2 (en) 2007-08-10 2009-02-19 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
EA201000516A1 (ru) 2007-09-20 2010-10-29 Кортекс Фармасеутикалс, Инк. 3-замещенные 1,2,3-триазин-4-оны и 3-замещенные 1,3-пиримидин-оны для усиления глутаматергических синаптических ответов

Also Published As

Publication number Publication date
AU2008287445A1 (en) 2009-02-19
ES2560095T3 (es) 2016-02-17
WO2009023126A2 (en) 2009-02-19
CA2702292A1 (en) 2009-02-19
EP2187888A4 (en) 2010-09-08
US8110584B2 (en) 2012-02-07
SG163526A1 (en) 2010-08-30
WO2009023126A3 (en) 2009-04-30
RU2010107795A (ru) 2011-09-10
US20110003835A1 (en) 2011-01-06
CN101862330A (zh) 2010-10-20
NZ583823A (en) 2011-07-29
CN101896183B (zh) 2013-11-27
JP2010215630A (ja) 2010-09-30
EP2187888B1 (en) 2015-10-21
US9492440B2 (en) 2016-11-15
JP2010535858A (ja) 2010-11-25
JP5576277B2 (ja) 2014-08-20
US8263591B2 (en) 2012-09-11
CA2695742A1 (en) 2009-02-19
RU2010106975A (ru) 2011-09-20
EP2187888A2 (en) 2010-05-26
BRPI0823262A2 (pt) 2013-09-24
KR20100045507A (ko) 2010-05-03
HK1147677A1 (en) 2011-08-19
CA2695742C (en) 2012-11-27
US20130190351A1 (en) 2013-07-25
MX2010001630A (es) 2010-03-15
CN101896183A (zh) 2010-11-24
KR20100051678A (ko) 2010-05-17
US20100286177A1 (en) 2010-11-11
ZA201001691B (en) 2010-11-24
AU2008287445A2 (en) 2010-03-25
AU2010200563A1 (en) 2010-03-04
BRPI0814149A2 (pt) 2011-09-13

Similar Documents

Publication Publication Date Title
MX2009012430A (es) Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas.
SG163526A1 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
MX2010002890A (es) 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas.
de la Hoz-Aizpurua et al. Sleep bruxism. Conceptual review and update
MX2009004071A (es) Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos.
GEP20104937B (en) Histamine-3 receptor antagonists
WO2007088450A3 (en) Chromane antagonist of the h-3 receptor
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
Giordano et al. Obstructive sleep apnea in Prader-Willi syndrome: risks and advantages of adenotonsillectomy
ATE457985T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
Askenasy Approaching disturbed sleep in late Parkinson's disease: first step toward a proposal for a revised UPDRS
JP2007513968A5 (es)
WO2008153958A3 (en) Crystalline forms of (r)-1-{2-[4&#39;- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
JP2008507550A5 (es)
JP2010529130A5 (es)
Rizzi et al. Periodic limbic movement disorder during sleep as diabetes-related syndrome? A polysomnographic study
Chou Adverse events from the treatment of Parkinson's disease
WO2007061741A3 (en) Modulators of the h3 receptor useful for the treatment of disorders related thereto
MX2011008060A (es) Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.
NO20090972L (no) Pyrazolo[1,5-A]pyrimidiner, fremgangsmater, anvendelser og sammensetninger
Yerram et al. Sleep Issues in Motor Neuron Diseases
Molano Sleep in mild cognitive impairment and dementia.
Irfan et al. Sleep disturbances in neurodegenerative disorders
Malhotra et al. 26 Chapter Sleep and Other Neurologic Diseases
Rosenberg What have we learned from recent clinical trials in AD?

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration